Literature DB >> 25218176

Time course of cytokine upregulation in the lacrimal gland and presence of autoantibodies in a predisposed mouse model of Sjögren's Syndrome: the influence of sex hormones and genetic background.

Stefanie Czerwinski1, Safinaz Mostafa1, Vanessa Seamon Rowan1, Ana Maria Azzarolo2.   

Abstract

Sjögren's Syndrome (SS) is a chronic, inflammatory autoimmune disease characterized by lacrimal gland lymphocytic infiltration and epithelial cell death, as well as by the presence of serum autoantibodies. Although the symptoms of this syndrome are well characterized, patients are not diagnosed until 5-10 years into disease progression; furthermore, the early series of events leading to the initiation of SS are not well understood. In order to better understand the early events of the disease, we have been using ovariectomized (OVX) NOD.B10.H2(b) mice as a genetically predisposed model of SS. Previously, we have shown that removal of ovarian hormones through ovariectomy accelerated the symptoms of this disease, and in early events of SS in the lacrimal glands, lymphocytic infiltration preceded acinar cell apoptosis. To further elucidate the earlier events of this disease in the SS animal model, we investigated the expression and concentration of pro-inflammatory cytokines in the lacrimal glands as well as the presence of autoantibodies in both lacrimal glands and serum. Six weeks old NOD.B10.H2(b) and C57BL/10 control mice were either sham-operated, OVX, OVX and treated with 17β-estradiol (E2), or OVX and treated with dihydrotestosterone (DHT). Lacrimal glands were collected at 3, 7, 21, and 30 days after surgery and analyzed for cytokines IL-1β, TNF-α, IFN-γ, IL-10, and IL-4 gene expression by using quantitative RT-PCR and for cytokine levels using ELISA. Furthermore, anti-Ro/SSA and anti-La/SSB autoantibodies were measured in the serum and lacrimal glands supernatants using ELISA. The results of this study showed that OVX caused a significant increase in the expression and levels of the cytokines IL-1β, TNF-α, and IL-4 in the lacrimal glands of the NOD.B10.H2(b) mice starting at 3 days after OVX, while a significant increase of IL-10 gene expression and levels was observed only at later experimental time points. A small but significant increase in the expression of IL-1β and IL-4 was observed only at later experimental time points in the lacrimal glands of OVX C57BL/10 mice, while no significant changes in the expression of TNF-α and IL-10 were seen at any experimental times in this group. No significant differences were observed in the levels of the cytokines IL-1β, TNF-α, IL-4, and IL-10 in the lacrimal glands of the OVX C57BL/10 mice at any of the experimental times studied compared to the sham-operated group. IFN-γ was not detected in either mouse strains at the level of mRNA and protein. OVX in the NOD.B10.H2(b) mice also caused an increase in the levels of anti-Ro/SSA autoantibodies in the serum only, while no anti-La/SSB autoantibodies were found in the serum or lacrimal gland supernatants. Physiological doses of E2 or DHT at time of OVX prevented the upregulation of cytokines and the presence of anti-Ro/SSA autoantibodies in these animals. These results showed that a decrease in the concentrations of ovarian hormones in the genetically predisposed mice accelerated the onset of the disease by upregulating various pro-inflammatory cytokines at different time points and promoting the formation of anti-Ro/SSA serum autoantibodies, creating an environment favorable for the initiation of SS. Published by Elsevier Ltd.

Entities:  

Keywords:  Anti-La/SSB; Anti-Ro/SSA; Cytokines; Lacrimal glands; NOD.B10.H2(b); Sex hormones; Sjögren's Syndrome

Mesh:

Substances:

Year:  2014        PMID: 25218176      PMCID: PMC4254156          DOI: 10.1016/j.exer.2014.09.001

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  24 in total

Review 1.  The meaning of anti-Ro and anti-La antibodies in primary Sjögren's syndrome.

Authors:  Gabriela Hernández-Molina; Gustavo Leal-Alegre; Martha Michel-Peregrina
Journal:  Autoimmun Rev       Date:  2010-09-15       Impact factor: 9.754

Review 2.  Effect of inflammation on lacrimal gland function.

Authors:  Driss Zoukhri
Journal:  Exp Eye Res       Date:  2005-11-23       Impact factor: 3.467

3.  Utilization of the non-obese diabetic (NOD) mouse as an animal model for the study of secondary Sjögren's syndrome.

Authors:  M G Humphreys-Beher; Y Hu; Y Nakagawa; P L Wang; K R Purushotham
Journal:  Adv Exp Med Biol       Date:  1994       Impact factor: 2.622

4.  A dual role for interferon-gamma in the pathogenesis of Sjogren's syndrome-like autoimmune exocrinopathy in the nonobese diabetic mouse.

Authors:  S Cha; J Brayer; J Gao; V Brown; S Killedar; U Yasunari; A B Peck
Journal:  Scand J Immunol       Date:  2004-12       Impact factor: 3.487

Review 5.  Sjögren's syndrome (SjS)-like disease of mice: the importance of B lymphocytes and autoantibodies.

Authors:  Cuong Quoc Nguyen; Seunghee Ro Cha; Ammon Broughton Peck
Journal:  Front Biosci       Date:  2007-01-01

6.  Cytokines in autoimmune lacrimal gland disease in MRL/MpJ mice.

Authors:  D A Jabs; R A Prendergast; E M Rorer; A P Hudson; J A Whittum-Hudson
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-10       Impact factor: 4.799

7.  Constitutively active NF-kappaB triggers systemic TNFalpha-dependent inflammation and localized TNFalpha-independent inflammatory disease.

Authors:  Jie Dong; Eijiro Jimi; Caroline Zeiss; Matthew S Hayden; Sankar Ghosh
Journal:  Genes Dev       Date:  2010-08-15       Impact factor: 11.361

8.  Curcumin modulates nuclear factor kappaB (NF-kappaB)-mediated inflammation in human tenocytes in vitro: role of the phosphatidylinositol 3-kinase/Akt pathway.

Authors:  Constanze Buhrmann; Ali Mobasheri; Franziska Busch; Constance Aldinger; Ralf Stahlmann; Azadeh Montaseri; Mehdi Shakibaei
Journal:  J Biol Chem       Date:  2011-06-13       Impact factor: 5.157

Review 9.  Dysfunction of lacrimal and salivary glands in Sjögren's syndrome: nonimmunologic injury in preinflammatory phase and mouse model.

Authors:  Toshiharu Hayashi
Journal:  J Biomed Biotechnol       Date:  2011-06-01

Review 10.  Novel aspects of Sjögren's syndrome in 2012.

Authors:  Angela Tincani; Laura Andreoli; Ilaria Cavazzana; Andrea Doria; Marta Favero; Maria-Giulia Fenini; Franco Franceschini; Andrea Lojacono; Giuseppe Nascimbeni; Amerigo Santoro; Francesco Semeraro; Paola Toniati; Yehuda Shoenfeld
Journal:  BMC Med       Date:  2013-04-04       Impact factor: 8.775

View more
  4 in total

1.  Sjögren's Syndrome is Associated With Reduced Lifetime Sex Hormone Exposure: A Case-Control Study.

Authors:  Sara S McCoy; Emmanuel Sampene; Alan N Baer
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-06-24       Impact factor: 4.794

2.  Mastitis associated with Sjögren's syndrome: a series of nine cases.

Authors:  Radjiv Goulabchand; Assia Hafidi; Ingrid Millet; Jacques Morel; Cédric Lukas; Sébastien Humbert; Sophie Rivière; Christian Gény; Christian Jorgensen; Alain Le Quellec; Hélène Perrochia; Philippe Guilpain
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

3.  Early Dry Eye Disease Onset in a NOD.H-2h4 Mouse Model of Sjögren's Syndrome.

Authors:  Lili Li; Kimberly J Jasmer; Jean M Camden; Lucas T Woods; Adam L Martin; Yong Yang; Maria Layton; Michael J Petris; Olga J Baker; Gary A Weisman; Carisa K Petris
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-06-01       Impact factor: 4.925

Review 4.  Sex Hormones, Growth Hormone, and the Cornea.

Authors:  Tina B McKay; Shrestha Priyadarsini; Dimitrios Karamichos
Journal:  Cells       Date:  2022-01-11       Impact factor: 6.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.